Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

NAMSA Expands Minneapolis Preclinical Laboratory to Meet Industry Demand for MedTech Research and Development Solutions

NAMSA, the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today the expansion of its Minneapolis preclinical research laboratory. This expansion will add 55,000 sq. ft. to the current 130,000 sq. ft. preclinical campus in Minneapolis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005326/en/

Image (Clockwise): Dr. Michael Conforti, DVM (APS Founder, Vice President-Preclinical Operations-NAMSA); Dr. Emily Drake, DVM (Sr. Director, Regional ISR/Veterinary Operations-NAMSA); and Christophe Berthoux (NAMSA CEO) review blueprints and expansion plans at NAMSA's Minneapolis preclinical laboratory facility. (Photo: Business Wire)

Image (Clockwise): Dr. Michael Conforti, DVM (APS Founder, Vice President-Preclinical Operations-NAMSA); Dr. Emily Drake, DVM (Sr. Director, Regional ISR/Veterinary Operations-NAMSA); and Christophe Berthoux (NAMSA CEO) review blueprints and expansion plans at NAMSA's Minneapolis preclinical laboratory facility. (Photo: Business Wire)

NAMSA, through its preclinical, interventional and surgical research services, provides medical device Sponsors a broad range of laboratory models and analysis tools, including state-of-the-art surgical instrumentation and catheterization labs, imaging capabilities and fully equipped surgical suites. With this expansion, the organization will increase capacity for early-stage feasibility studies and complex R&D investigations, while also adding additional surgical suites and catheterization laboratories.

“We are excited to announce the news of our expanded laboratory capacity at a time when there is an industry-wide challenge of increased lead-times for preclinical services and laboratory capacity,” commented Christophe Berthoux, NAMSA CEO. “With competitor-reported timelines of up to nine months for new preclinical projects, NAMSA is pleased to readily assist medical device innovators with the ability to conduct timely, high-quality safety and performance evaluations for early-stage R&D efforts through this expansion and increased capacity,” Berthoux concluded.

NAMSA’s Minneapolis preclinical laboratory expansion will occur in two stages with completion slated for April 2022 and December 2022, respectively.

Complimentary Consultations

NAMSA invites you to learn more about our preclinical capabilities, as well as our integrated preclinical-to-clinical solution for complex medical device development programs. Get in touch for a 30-minute complimentary consultation today: https://namsa.com/locations-contact/.

About NAMSA

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Web: namsa.com

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.